CEP-18770

CEP-18770

Catalog Number:
L002368956APE
Mfr. No.:
APE-A4009
Price:
$289
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          CEP-18770 is a novel, potent and reversible P2 threonine boronic acid inhibitor of proteasome that inhibits proteasome’s chymotrypsin-like activity, with the value of inhibition constant IC50 of 3.8 nM, by down-modulating the activity of nuclear factor-KB (NF-KB) as well as the expression of a few NF-KB downstream effectors. Preliminary results of multiple studies have shown that CEP-18770 exerts potent antitumor activities against human multiple myeloma (MM) cell lines by inducing apoptotic cell death, exhibits a strong antiangiogenic activity suppressing RANKL-induced osteoclastogenesis, and displays a favorable cytotoxicity profile towards normal cells including epithelial cells, bone marrow progenitors, and bone marrow-derived stromal cells.

      • Properties
        • Alternative Name
          [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid
          CAS Number
          847499-27-8
          Molecular Formula
          C21H28BN3O5
          Molecular Weight
          413.3
          Appearance
          A solid
          Purity
          98.02%
          Solubility
          insoluble in H2O; ≥16.75 mg/mL in DMSO; ≥32.27 mg/mL in EtOH with ultrasonic
          Storage
          Store at -20°C

          * For Research Use Only

      • Reference
        • 1. Sha Z, Schnell HM, et al. "Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation." J Cell Biol. 2018 Mar 13. pii: jcb.201708168. PMID:29535191

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.